Tuesday, 15 February 2022, 7:08 pmPress Release: MedCan Summit 2022 “MedCan 2022 successfully brought together New Zealand’s newest sector which ... Read More

LONDON–(BUSINESS WIRE)–Akanda Corp. (“Akanda” or the “Company”) today announced the appointment of Gila Jones, Gugu Dingaan and Bridget Baker to ... Read More

NEW YORK and TORONTO – TerrAscend Corp. (“TerrAscend” or the “Company”) (CSE: TER) (OTCQX: TRSSF), a leading North American cannabis operator, today announced the appointment of Charishma Kothari as SVP […]

HONG KONG, Feb 7, 2022 - (ACN Newswire) - SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that, on 21 January 2022, an Investigational New Drug application ("IND", for multiple sclerosis) for SN1011 has been filed with and accepted, on 28 January 2022, by the Center for Drug Evaluation (the "CDE") of the National Medical Products Administration of China (the "NMPA"). The Company plans to initiate the Phase II clinical study in China upon approval of the present IND. The present IND submission, once granted, will enable the Company to conduct comprehensive clinical development program in China which leads to indication for treatment of multiple sclerosis.

SN1011 is the Company's third generation, covalent reversible BTK inhibitor designed for higher selectivity, superior efficacy and improved safety for the long-term treatment of systemic lupus erythematous, pemphigus vulgaris, multiple sclerosis, rheumatoid arthritis, and other immunological diseases. SN1011 differentiates from existing BTK inhibitors currently available in the market, such as Ibrutinib, in terms of mechanism of action, affinity, selectivity and safety.

Dr. Shui On LEUNG, Chairman, Executive Director and Chief Executive Officer of SinoMab said that: "after the Company announced earlier the Completion of Enrollment in Phase III Clinical Trial in China for its Flagship Product, SM03, an IND application (for multiple sclerosis) for SN1011 has been filed with and accepted by the Center for the CDE of the NMPA, which will accelerate the progression of the Phase II clinical study and clinical development program related to indication for treatment of multiple sclerosis, fully reflecting the Company's efficient implementation of new drug R&D programs. We are absolutely confident in the enormous prospects of SN1011's clinical development. In the future, the Company will accelerate the program to further expand its product pipeline and strive to bring benefits to patients."

About SinoMab BioScience Limited
SinoMab BioScience Limited (stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company's flagship product SM03 is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis (RA) and is currently in Phase III clinical trial for rheumatoid arthritis in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Twelfth Five-Year Plan Period and the Thirteenth Five-Year Plan Period. In addition, the Company possesses other potential first-in-target and first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), pemphigus vulgaris (PV), non-Hodgkin's lymphoma (NHL), asthma, and other diseases with major unmet clinical needs.



Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comSinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that, on 21 January 2022,

Last week, Phylos Bioscience filed a federal court complaint against Silver Lion Farms in the District of Oregon. The complaint details that Phylos and Silver Lion had entered into a Letter of Engagement for Silver Lion to  purchase $2,954,250 worth of hemp seeds of two different varieties – 14,625,000 of AutoCBD seeds and 8,775,000 of

The post Hemp Litigation and the Plant Variety Protection Act appeared first on Harris Bricken.

Event Details Mon, Jan 24, 2022 at 6:30 PM Ludlow House, 139 Ludlow St, New York, NY, 10002 More info: https://www.eventbrite.com/e/psychedelic-panel-series-new-york-tickets-250350935387 On Monday, January 24 at 6:30 p.m., Dustin Robinson, Esq. CPA, is bringing his Psychedelic Series that takes place monthly at Soho Beach House Miami to Ludlow House in New York. Hosted by Robinson, the panel will feature […]

CBD Water: Big Market Opportunity Or Just The Next Crazy CBD-Infused Product?

Is CBD water going to be a big thing or just a niche health product?

The post CBD Water: Big Market Opportunity Or Just The Next Crazy CBD-Infused Product? appeared first on The Fresh Toast.

The CBD water market is sinking at a fast rate right now. The questionable product design, the volatile nature of cannabidiol, and the hefty price tags all contributed to this massive downfall. The product has several utilities, but the downsides surrounding it are guaranteed to put people off. This does not mean you should not try the product. If you prefer convenience without worrying about the cost, you can carry on with these products. You would do well to exercise caution by purchasing only the recently produced bottles from licensed dispensaries. For people that care about the impact of this product on their wallets, it is better to avoid CBD water now until the manufacturers are ready to do what's right. For its market to start swimming, CBD water has to live up to its hype.

DUBLIN–(BUSINESS WIRE)–The “Global Genetic Testing Market Forecasts for Applications and Technologies 2021-2025 – COVID-19 Pandemic Impact Updates with Executive and Consultant Guides” report has been added to ResearchAndMarkets.com’s offering. This report forecasts the market size out to 2025. The report includes detailed breakouts for 14 countries and 5 regions. Is genomic cancer testing bouncing back? […]

The post Global Genetic Testing Markets, Applications and Technologies Report 2022 – ResearchAndMarkets.com appeared first on Fintech News.

Revelation Biosciences, Inc., a clinical-stage life sciences company focused on the development of immunologic‑based therapies for the prevention and treatment of disease, and Petra Acquisition, Inc., today announced they have entered into a definitive merger agreement for a business combination that will result in Revelation becoming a publicly-traded company.